Vidofludimus (hemicalcium)
Product Specifications
UNSPSC Description
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for farnesoid X receptor (FXR). Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver by targeting FXR[1][2][3].
Target Antigen
Dihydroorotate Dehydrogenase; FXR; Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation;Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/vidofludimus-hemicalcium.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=C(C(NC2=CC=C(C3=CC=CC(OC)=C3)C=C2F)=O)CCC1)O.[Ca].[1/2]
Molecular Weight
375.40
References & Citations
[1]Yanlin Zhu, et al. Repositioning an Immunomodulatory Drug Vidofludimus as a Farnesoid X Receptor Modulator With Therapeutic Effects on NAFLD. Front Pharmacol. 2020 May 14;11:590. |[2]Andreas Muehler, et al. Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020 Aug;43:102129. |[3]Leo R Fitzpatrick, et al. Vidofludimus inhibits colonic interleukin-17 and improves hapten-induced colitis in rats by a unique dual mode of action. J Pharmacol Exp Ther. 2012 Sep;342(3):850-60.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-14908A/Vidofludimus-hemicalcium-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-14908A/
Clinical Information
Phase 2
CAS Number
1354012-90-0
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
34776126 3 x 1.0μg DNA
Olr907 CRISPRa sgRNA lentivector (set of three targets)(Rat)
Ask
View Details 